Core Viewpoint - The company Anke Bio (300009) is actively advancing its clinical trials for various innovative drugs, indicating a stable operational status and no undisclosed risks [1] Group 1: Clinical Trials Progress - The clinical trials for the company's in-development products are progressing well, with "HuA21 injection" having completed the enrollment of participants for its Ib/II phase and planning to initiate III phase trials based on interim analysis results [1] - "AK2024 injection," targeting HER2, is currently in I phase clinical trials, showing significant synergistic effects in inhibiting HER2-positive tumor cell proliferation compared to other treatments [1] - "HK010 injection," a dual antibody drug, has completed the enrollment of its first participant in II phase clinical trials [1] Group 2: Additional Projects and Collaborations - "AK2017 injection," a recombinant human growth hormone-Fc fusion protein, is progressing smoothly in III phase clinical trials [1] - The "AK1012 project," aimed at treating respiratory syncytial virus-induced lower respiratory infections in children, has completed I phase trials and is now in II/III phase trials [1] - The company's affiliate, Boshengji, has its PA3-17 injection included in breakthrough therapy designation and is entering critical II phase clinical trials, aiming to complete patient enrollment within a year [1] - Yuan Song Bio, another affiliate, has received IND approval for its lead product "recombinant L-IFN adenovirus injection," which is currently in IIa phase clinical trials in China [1] - The company is collaborating with Afana to develop AFN0328 injection for treating HPV16/18 precancerous lesions, with I phase clinical trials showing very promising data [1]

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has decided to terminate its plan to establish a joint venture with AstraZeneca Investment (China) Co., Ltd. due to significant changes in the market environment and increased investment risks in the vaccine industry [1] Group 1: Joint Venture Details - The joint venture was initially planned to be established in March 2025, with both companies holding a 50% stake and a registered capital of approximately 345 million RMB, with a total investment of around 400 million USD [1] - The decision to terminate the joint venture was made after careful evaluation and friendly consultation among the parties involved, as the new vaccine industry investment risks were deemed too high [1] Group 2: Impact on Company Operations - As of now, the joint venture has not been established, and Kangtai Biological has not made any actual capital contributions [1] - The company stated that this termination will not have a significant impact on its existing business, financial status, or operational conditions [1] - Kangtai Biological will continue to pursue its strategy of "internal innovation + external expansion" and deepen its international business layout [1]

Core Viewpoint - The company has decided to terminate its plans for establishing a joint venture due to significant changes in the market environment and high investment risks in the vaccine industry [1] Group 1: Company Decisions - The company's board of directors approved the proposal to terminate the investment in a joint venture during the eighth board meeting on February 6, 2026 [1] - The decision was made after the board assessed the severe downward pressure on the vaccine industry and the associated high risks of new investments [1] - The company will authorize management to finalize and sign the termination agreement with partners, relieving all parties from related obligations and responsibilities upon termination [1] Group 2: Market Context - The termination of the investment is aimed at responding to market changes and controlling investment risks [1] - The company anticipates that this decision will not have a significant adverse impact on its existing business and financial condition [1]

Group 1 - The core index of the biotechnology sector, the Biotechnology Economy Index (970038), closed at 2177.69 points, down 0.42% on February 6, with a trading volume of 18.133 billion yuan and a turnover rate of 1.61% [1] - Among the constituent stocks of the index, 15 stocks rose, with Tigermed leading the gainers at a 3.06% increase, while 34 stocks declined, with Hualan Vaccine leading the losers at a 3.48% decrease [1] Group 2 - The net outflow of main funds from the Biotechnology Economy Index constituents totaled 484 million yuan, while the net inflow from speculative funds was 118 million yuan, and the net inflow from retail investors was 366 million yuan [2] - Detailed fund flow information for the constituent stocks is available in the accompanying table [2]

Core Viewpoint - The announcement of the New Drug Application (NDA) acceptance for TY-9591, a new generation EGFR-TKI inhibitor targeting brain metastases from non-small cell lung cancer (NSCLC), marks a significant milestone for the company and the treatment landscape for lung cancer patients in China [1][3]. Group 1: Drug Development and Clinical Trials - The NDA for TY-9591 has been officially accepted by the National Medical Products Administration (NMPA) in China, making it the first new generation EGFR-TKI specifically for lung cancer brain metastases [1][3]. - The NDA submission is based on results from a pivotal clinical study (ESAONA) that evaluated the efficacy and safety of TY-9591 compared to Osimertinib in NSCLC patients with brain metastases [3][4]. - The interim analysis of the ESAONA study showed an intracranial objective response rate (iORR) of 92.8% for the TY-9591 group compared to 76.1% for the Osimertinib group, indicating a statistically significant difference [4]. Group 2: Company Strategy and Future Plans - The submission of the NDA for TY-9591 represents a critical milestone for the company, indicating its entry into the commercialization phase and its commitment to addressing unmet clinical needs in cancer treatment [6][8]. - The company plans to continue exploring combination therapies and further clinical research to meet the clinical demands of patients with advanced NSCLC [5][6]. - The company has developed over ten innovative products since its establishment in 2017, focusing on next-generation kinase inhibitors to fulfill unmet clinical needs in cancer treatment [8].

Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) has announced that its New Drug Application (NDA) for the self-developed drug, Tyrosine-9591 (甲磺酸艾多替尼片), targeting brain metastases of non-small cell lung cancer (NSCLC), has been officially accepted by the National Medical Products Administration (NMPA) in China, marking it as the first next-generation EGFR-TKI inhibitor for lung cancer brain metastases [1][5]. Group 1: Drug Development and Clinical Trials - The NDA submission is based on a pivotal registration clinical study (ESAONA) conducted in China, which is a multi-center, randomized, open-label, positive-controlled trial aimed at evaluating the efficacy and safety of Tyrosine-9591 compared to Osimertinib in NSCLC patients with brain metastases [3]. - The mid-term analysis of the ESAONA study, presented at the WCLC2025 conference, showed an intracranial objective response rate (iORR) of 92.8% for the Tyrosine-9591 group compared to 76.1% for the Osimertinib group, indicating a statistically significant difference [4]. - Tyrosine-9591 is designed for first-line treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletions or L858R mutations and central nervous system (CNS) metastases [2]. Group 2: Company Strategy and Future Outlook - The acceptance of the NDA into the priority review process by the NMPA is expected to expedite the drug's market launch, with ongoing studies on both monotherapy and combination therapy for Tyrosine-9591 [5]. - The company emphasizes its commitment to addressing unmet clinical needs and continues to explore clinical research for combination therapies to better serve patients with lung cancer brain metastases [6]. - The submission of the NDA represents a significant milestone for the company, marking its entry into the commercialization phase and reflecting its dedication to innovative drug development in the oncology field [6][8].

Core Insights - The approval of VELSIPITY® (Argenine Acquimod Tablets) by the NMPA marks a significant advancement for the company in the treatment of moderate to severe active ulcerative colitis (UC) in adults, filling a critical gap in the market [1][2] - The drug is expected to reach peak sales of 5 billion RMB, becoming a core product alongside the existing drug in the nephrology field, indicating a new phase of rapid growth for the company [1][6] Group 1: Product Approval and Market Potential - VELSIPITY® is a next-generation high-selectivity S1P receptor modulator that offers rapid onset and effective deep mucosal healing, providing a new first-line treatment option for UC patients [1][3] - The incidence of UC in China is rising, with projections indicating an increase from approximately 980,000 patients in 2025 to about 1.5 million by 2031, highlighting the growing need for effective treatments [2] - Current treatment options are limited, with only 24% of UC patients achieving mucosal healing, underscoring the unmet clinical needs that VELSIPITY® aims to address [2][3] Group 2: Clinical Efficacy and Recognition - Clinical trials have shown that VELSIPITY® has a clinical remission rate of 48.1% and a mucosal healing rate of 51.9% after 40 weeks of maintenance treatment, demonstrating its significant clinical advantages [3][4] - The drug has been included in major international clinical guidelines, such as the 2024 AGA guidelines and the 2025 ACG guidelines, receiving strong recommendations for its use in moderate to severe UC [4] Group 3: Commercialization Strategy and Growth - The company has developed a comprehensive A2MS (Access, Medical, Market, Sales) operational system to efficiently promote VELSIPITY®'s market entry and maximize its therapeutic value [5][6] - The approval of VELSIPITY® signifies a major breakthrough in the autoimmune disease sector, enhancing the company's product matrix and expected to significantly boost revenue and profitability [6][7] - The company aims to achieve over 10 billion RMB in revenue by 2028 and over 15 billion RMB by 2030, with a projected annual growth rate exceeding 50% from 2025 to 2030 [7]

Group 1 - The core product of the company, the TROP2-targeted antibody-drug conjugate (ADC) sac-TMT, has received approval from the National Medical Products Administration (NMPA) in China for its fourth indication, aimed at treating adult patients with HR+/HER2- breast cancer who have previously undergone endocrine therapy and at least one line of chemotherapy in the advanced disease stage [1][2] - The approval is based on positive results from the OptiTROP-Breast02 Phase 3 clinical study, which has been selected for a breakthrough abstract presentation at the 2025 European Society for Medical Oncology (ESMO) conference [1] Group 2 - The company has renewed a framework agreement with China Resources Kolun for research and development-related materials, extending until 2026 [2]

Core Viewpoint - The approval of the antibody-drug conjugate sac-TMT (also known as SKB264/MK-2870) for a new indication in treating HR+/HER2- breast cancer patients in China marks a significant milestone for the company, expanding its therapeutic applications in the oncology space [1] Group 1: Regulatory Approval - The National Medical Products Administration (NMPA) of China has approved sac-TMT for treating adult patients with unresectable or metastatic HR+/HER2- breast cancer who have previously received endocrine therapy and at least one line of chemotherapy [1] - This approval represents the fourth indication for sac-TMT in China [1] Group 2: Clinical Study Results - The approval is based on positive results from the OptiTROP-Breast023 phase II clinical study, which was presented at the 2025 European Society for Medical Oncology (ESMO) conference [1] - The OptiTROP-Breast02 study demonstrated that sac-TMT significantly improved progression-free survival (PFS) compared to chemotherapy, with a PFS of 8.3 months versus 4.1 months (hazard ratio (HR) of 0.35; 95% confidence interval (CI): 0.26-0.48; p<0.0001) [2] - Consistent PFS benefits were observed across various subgroups, including those with different HER2 expression levels and prior chemotherapy lines [2] - The overall survival (OS) trend and objective response rate (ORR) were also notably improved in the sac-TMT group, with an ORR of 41.5% compared to 24.1% in the chemotherapy group [2] Group 3: Ongoing Research - Ongoing phase III clinical studies are evaluating sac-TMT, both alone and in combination with pembrolizumab, for HR+/HER2- breast cancer patients who have previously received endocrine therapy but not chemotherapy [3]

Core Viewpoint - The approval of the antibody-drug conjugate sac-TMT (also known as SKB264/MK-2870) for a new indication in treating HR+/HER2- breast cancer in China represents a significant advancement for the company and the industry, particularly for patients who have undergone prior endocrine therapy and at least one line of chemotherapy [1] Group 1: Regulatory Approval - The National Medical Products Administration (NMPA) of China has approved sac-TMT for treating adult patients with unresectable or metastatic HR+/HER2- breast cancer who have previously received endocrine therapy and at least one line of chemotherapy [1] - This approval marks the fourth indication for sac-TMT in China [1] Group 2: Clinical Study Results - The approval is based on positive results from the OptiTROP-Breast023 phase II clinical study, which was presented at the 2025 European Society for Medical Oncology (ESMO) conference [1] - The OptiTROP-Breast02 study evaluated the efficacy and safety of sac-TMT compared to physician's choice of chemotherapy in patients with unresectable or metastatic HR+/HER2- breast cancer, with 95.7% of patients having visceral metastases and 75.9% having liver metastases at enrollment [2] - The study showed a significant improvement in progression-free survival (PFS) for the sac-TMT group compared to the chemotherapy group (8.3 months vs. 4.1 months; hazard ratio (HR), 0.35; 95% confidence interval (CI): 0.26-0.48; p<0.0001) [2] - Consistent PFS benefits were observed across predefined subgroups, including those with HER2 expression of 0 and low expression [2] - The overall survival (OS) benefit trend and objective response rate (ORR) were also significantly higher in the sac-TMT group (41.5% vs. 24.1%) [2] Group 3: Ongoing Research - Ongoing phase III clinical studies are evaluating sac-TMT, with or without pembrolizumab, for treating HR+/HER2- breast cancer patients who have previously received endocrine therapy but not chemotherapy, both globally and in China [3]